MY008 / Createrna - LARVOL DELTA

A Phase 2 Dose-Finding Trial of MY008211A in Complement Inhibitor–Naive Patients with Paroxysmal Nocturnal Hemoglobinuria and Signs of Active Hemolysis (ASH 2024) - "Improvements in secondary EPs, including fatigue, were of similar magnitude across dosage groups. This, together with the evidenced safety profile, supports the continued development of MY008211A."

Clinical • P2 data • Complement-mediated Rare Disorders • Fatigue • Hematological Disorders • Infectious Disease • Meningococcal Infections • Paroxysmal Nocturnal Hemoglobinuria • Pneumonia • Rare Diseases • Respiratory Diseases • Thrombosis • CFB

Study of Safety and Efficacy of MY008211A in in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) (clinicaltrials.gov) - P2 | N=40 | Not yet recruiting | Sponsor: Wuhan Createrna Science and Technology Co., Ltd | Trial completion date: Dec 2025 ➔ Dec 2027 | Trial primary completion date: Jul 2025 ➔ Jul 2027

Trial completion date • Trial primary completion date • Complement-mediated Rare Disorders • Hematological Disorders • Paroxysmal Nocturnal Hemoglobinuria • Rare Diseases

A Study of MY008211A in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) (clinicaltrials.gov) - P2 | N=34 | Completed | Sponsor: Wuhan Createrna Science and Technology Co., Ltd | Recruiting ➔ Completed | Trial completion date: Jul 2024 ➔ Nov 2024

Trial completion • Trial completion date • Complement-mediated Rare Disorders • Hematological Disorders • Paroxysmal Nocturnal Hemoglobinuria • Rare Diseases

Long-term Safety and Tolerability of MY008211A Tablets in Patients With Paroxysmal Nocturnal Hemoglobinuria (clinicaltrials.gov) - P2/3 | N=120 | Recruiting | Sponsor: Wuhan Createrna Science and Technology Co., Ltd

New P2/3 trial • Complement-mediated Rare Disorders • Hematological Disorders • Paroxysmal Nocturnal Hemoglobinuria • Rare Diseases

Study of Safety and Efficacy of MY008211A in Patients With Residual Anemia Despite Anti-C5 Antibody Treatment (clinicaltrials.gov) - P3 | N=20 | Recruiting | Sponsor: Wuhan Createrna Science and Technology Co., Ltd

New P3 trial • Anemia • Complement-mediated Rare Disorders • Hematological Disorders • Paroxysmal Nocturnal Hemoglobinuria • Rare Diseases

Study of Safety and Efficacy of MY008211A in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor Therapy (clinicaltrials.gov) - P3 | N=66 | Recruiting | Sponsor: Wuhan Createrna Science and Technology Co., Ltd

New P3 trial • Complement-mediated Rare Disorders • Hematological Disorders • Paroxysmal Nocturnal Hemoglobinuria • Rare Diseases

Study to Evaluate the Efficacy and Safety of MY008211A in Subjects with Primary Immunoglobulin a Nephropathy (IgAN) (clinicaltrials.gov) - P2 | N=72 | Not yet recruiting | Sponsor: Wuhan Createrna Science and Technology Co., Ltd

New P2 trial • Glomerulonephritis • IgA Nephropathy • Renal Disease

To Evaluate the Effect of Single Oral Dose of MY008211A Tablets on QTc Interval in Healthy Subjects (clinicaltrials.gov) - P1 | N=16 | Not yet recruiting | Sponsor: Wuhan Createrna Science and Technology Co., Ltd

New P1 trial • Complement-mediated Rare Disorders • Hematological Disorders • Paroxysmal Nocturnal Hemoglobinuria • Rare Diseases

Study of Safety and Efficacy of MY008211A in in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) (clinicaltrials.gov) - P2 | N=40 | Not yet recruiting | Sponsor: Wuhan Createrna Science and Technology Co., Ltd

Trial completion date • Trial initiation date • Trial primary completion date • Complement-mediated Rare Disorders • Hematological Disorders • Paroxysmal Nocturnal Hemoglobinuria • Rare Diseases

Study of Safety and Efficacy of MY008211A in in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) (clinicaltrials.gov) - P2 | N=40 | Not yet recruiting | Sponsor: Wuhan Createrna Science and Technology Co., Ltd

New P2 trial • Complement-mediated Rare Disorders • Hematological Disorders • Paroxysmal Nocturnal Hemoglobinuria • Rare Diseases

A Study of MY008211A in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) (clinicaltrials.gov) - P2 | N=40 | Recruiting | Sponsor: Wuhan Createrna Science and Technology Co., Ltd

New P2 trial • Complement-mediated Rare Disorders • Hematological Disorders • Paroxysmal Nocturnal Hemoglobinuria • Rare Diseases

A Study of Multiple Ascending Doses MY008211A in Healthy Adults (clinicaltrials.gov) - P1 | N=40 | Completed | Sponsor: Wuhan Createrna Science and Technology Co., Ltd | Active, not recruiting ➔ Completed | N=30 ➔ 40

Enrollment change • Trial completion • Complement-mediated Rare Disorders • Hematological Disorders • Paroxysmal Nocturnal Hemoglobinuria • Rare Diseases

A Study of Single-dose MY008211A in Healthy Adults (clinicaltrials.gov) - P1 | N=63 | Completed | Sponsor: Wuhan Createrna Science and Technology Co., Ltd | Active, not recruiting ➔ Completed | N=46 ➔ 63

Enrollment change • Trial completion • Complement-mediated Rare Disorders • Hematological Disorders • Paroxysmal Nocturnal Hemoglobinuria • Rare Diseases

A Study of Multiple Ascending Doses MY008211A in Healthy Adults (clinicaltrials.gov) - P1 | N=30 | Active, not recruiting | Sponsor: Wuhan Createrna Science and Technology Co., Ltd

New P1 trial • Complement-mediated Rare Disorders • Hematological Disorders • Paroxysmal Nocturnal Hemoglobinuria • Rare Diseases

Effect of Food on Pharmacokinetics of MY008211A Tablets in Healthy Adult Subjects (clinicaltrials.gov) - P1 | N=12 | Completed | Sponsor: Wuhan Createrna Science and Technology Co., Ltd

New P1 trial • Complement-mediated Rare Disorders • Hematological Disorders • Paroxysmal Nocturnal Hemoglobinuria • Rare Diseases

A Study of Single-dose MY008211A in Healthy Adults (clinicaltrials.gov) - P1 | N=46 | Active, not recruiting | Sponsor: Wuhan Createrna Science and Technology Co., Ltd

New P1 trial • Complement-mediated Rare Disorders • Hematological Disorders • Paroxysmal Nocturnal Hemoglobinuria • Rare Diseases